The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
There is an urgent need for anti-virals targeting SARS-CoV-2. One of the most promising viral targets is the main protease of SARS-CoV-2, which is essential for viral replication and has no human analogue. Here, Abdelnabi et al. show that one of the most promising anti-virals (PF-07321332), currentl...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-02-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-022-28354-0 |
| _version_ | 1819281045686583296 |
|---|---|
| author | Rana Abdelnabi Caroline S. Foo Dirk Jochmans Laura Vangeel Steven De Jonghe Patrick Augustijns Raf Mols Birgit Weynand Thanaporn Wattanakul Richard M. Hoglund Joel Tarning Charles E. Mowbray Peter Sjö Fanny Escudié Ivan Scandale Eric Chatelain Johan Neyts |
| author_facet | Rana Abdelnabi Caroline S. Foo Dirk Jochmans Laura Vangeel Steven De Jonghe Patrick Augustijns Raf Mols Birgit Weynand Thanaporn Wattanakul Richard M. Hoglund Joel Tarning Charles E. Mowbray Peter Sjö Fanny Escudié Ivan Scandale Eric Chatelain Johan Neyts |
| author_sort | Rana Abdelnabi |
| collection | DOAJ |
| description | There is an urgent need for anti-virals targeting SARS-CoV-2. One of the most promising viral targets is the main protease of SARS-CoV-2, which is essential for viral replication and has no human analogue. Here, Abdelnabi et al. show that one of the most promising anti-virals (PF-07321332), currently in clinical trials, protects against SARS-CoV-2 alpha, beta and delta variant infection and provide evidence of reduced transmission. |
| first_indexed | 2024-12-24T00:53:27Z |
| format | Article |
| id | doaj.art-8a988a1b7f644a20bb1a138315f14db0 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-12-24T00:53:27Z |
| publishDate | 2022-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-8a988a1b7f644a20bb1a138315f14db02022-12-21T17:23:32ZengNature PortfolioNature Communications2041-17232022-02-011311910.1038/s41467-022-28354-0The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concernRana Abdelnabi0Caroline S. Foo1Dirk Jochmans2Laura Vangeel3Steven De Jonghe4Patrick Augustijns5Raf Mols6Birgit Weynand7Thanaporn Wattanakul8Richard M. Hoglund9Joel Tarning10Charles E. Mowbray11Peter Sjö12Fanny Escudié13Ivan Scandale14Eric Chatelain15Johan Neyts16KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and ChemotherapyKU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and ChemotherapyKU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and ChemotherapyKU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and ChemotherapyKU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and ChemotherapyKU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Drug Delivery & DispositionKU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Drug Delivery & DispositionKU Leuven Department of Imaging and Pathology, Translational Cell and Tissue ResearchMahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol UniversityMahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol UniversityMahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol UniversityDrugs for Neglected Diseases initiativeDrugs for Neglected Diseases initiativeDrugs for Neglected Diseases initiativeDrugs for Neglected Diseases initiativeDrugs for Neglected Diseases initiativeKU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and ChemotherapyThere is an urgent need for anti-virals targeting SARS-CoV-2. One of the most promising viral targets is the main protease of SARS-CoV-2, which is essential for viral replication and has no human analogue. Here, Abdelnabi et al. show that one of the most promising anti-virals (PF-07321332), currently in clinical trials, protects against SARS-CoV-2 alpha, beta and delta variant infection and provide evidence of reduced transmission.https://doi.org/10.1038/s41467-022-28354-0 |
| spellingShingle | Rana Abdelnabi Caroline S. Foo Dirk Jochmans Laura Vangeel Steven De Jonghe Patrick Augustijns Raf Mols Birgit Weynand Thanaporn Wattanakul Richard M. Hoglund Joel Tarning Charles E. Mowbray Peter Sjö Fanny Escudié Ivan Scandale Eric Chatelain Johan Neyts The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern Nature Communications |
| title | The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern |
| title_full | The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern |
| title_fullStr | The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern |
| title_full_unstemmed | The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern |
| title_short | The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern |
| title_sort | oral protease inhibitor pf 07321332 protects syrian hamsters against infection with sars cov 2 variants of concern |
| url | https://doi.org/10.1038/s41467-022-28354-0 |
| work_keys_str_mv | AT ranaabdelnabi theoralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT carolinesfoo theoralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT dirkjochmans theoralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT lauravangeel theoralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT stevendejonghe theoralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT patrickaugustijns theoralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT rafmols theoralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT birgitweynand theoralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT thanapornwattanakul theoralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT richardmhoglund theoralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT joeltarning theoralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT charlesemowbray theoralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT petersjo theoralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT fannyescudie theoralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT ivanscandale theoralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT ericchatelain theoralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT johanneyts theoralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT ranaabdelnabi oralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT carolinesfoo oralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT dirkjochmans oralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT lauravangeel oralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT stevendejonghe oralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT patrickaugustijns oralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT rafmols oralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT birgitweynand oralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT thanapornwattanakul oralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT richardmhoglund oralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT joeltarning oralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT charlesemowbray oralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT petersjo oralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT fannyescudie oralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT ivanscandale oralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT ericchatelain oralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern AT johanneyts oralproteaseinhibitorpf07321332protectssyrianhamstersagainstinfectionwithsarscov2variantsofconcern |